MedTrace Logo

Long-term Experience With Abatacept SC in Routine Clinical Practice

NCT02090556 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2954

Last updated 2022-01-19

No results posted yet for this study

Summary

The purpose of this study is to estimate the retention rate of Abatacept SC over 24 months in routine clinical practice, in rheumatoid arthritis patients, in each country involved in the study. The purpose of the UK substudy is to explore whether integrating self-assessment into routine care could maintain tight control (of inflammation/disease activity) and at potentially lower cost resulting in improved health outcomes and cost-effectiveness.

Conditions

Sponsors & Collaborators

  • inVentiv Health Clinical

    collaborator OTHER

  • PharmaNet

    collaborator INDUSTRY

  • Bristol-Myers Squibb

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-26
Primary Completion
2019-01-29
Completion
2019-01-29

Countries

  • Australia
  • Austria
  • France
  • Germany
  • Greece
  • Italy
  • Monaco
  • Netherlands
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02090556 on ClinicalTrials.gov